EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury

Rebecca M Kandell iD, Jason R Wu iD, Ester J Kwon iD

Advanced Materials · 2024-08 · 36 (31)

DOI: 10.1002/adma.202301738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 02.06.2024. Verfasst von Rebecca M Kandell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, 92093, USA. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Azides, Fibrinogen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI, NHLBI NIH HHS, National Science Foundation Graduate Research Fellowship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury (TBI) is a critical public health concern, yet there are no therapeutics available to improve long‐term outcomes. Drug delivery to TBI remains a challenge due to the blood‐brain barrier and increased intracranial pressure. In this work, a chemical targeting approach to improve delivery of materials to the injured brain, is developed. It is hypothesized that the provisional fibrin matrix can be harnessed as an injury‐specific scaffold that can be targeted by materials via click chemistry. To accomplish this, the brain clot is engineered in situ by delivering fibrinogen modified with strained cyclooctyne (SCO) moieties, which incorporated into the injury lesion and is retained there for days. Improved intra‐injury capture and retention of diverse, clickable azide‐materials including a small molecule azide‐dye, 40 kDa azide‐PEG nanomaterial, and a therapeutic azide‐protein in multiple dosing regimens is subsequently observed. To demonstrate therapeutic translation of this approach, a reduction in reactive oxygen species levels in the injured brain after delivery of the antioxidant catalase, is achieved. Further, colocalization between azide and SCO‐fibrinogen is specific to the brain over off‐target organs. Taken together, a chemical targeting strategy leveraging endogenous clot formation is established which can be applied to improve therapeutic delivery after TBI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain Injuries, TraumaticAzidesFibrinogenAnimalsClick ChemistryFibrinReactive Oxygen SpeciesBrainMiceCatalasePolyethylene GlycolsRatsCyclooctanesDrug Delivery SystemsBlood-Brain Barrier

Stichwörter der Autor:innen

catalaseclick chemistrydrug deliveryfibrinogennanomaterial

Substanzen

AzidesFibrinogenFibrinReactive Oxygen SpeciesCatalasePolyethylene GlycolsCyclooctanes

Autor:innen und Institutionen

  • Shu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA, 92093, USA.

ORCID-Profile: Rebecca M Kandell, Jason R Wu, Ester J Kwon

Förderung

  • NHLBI
  • NHLBI NIH HHS
  • National Science Foundation Graduate Research Fellowship Program
  • NIH HHS
  • National Science Foundation
  • NINDS NIH HHS
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Kandell, R. M., Wu, J. R., & Kwon, E. J. (2024). Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury. Advanced Materials, 36(31). https://doi.org/10.1002/adma.202301738

Vancouver

Kandell RM, Wu JR, Kwon EJ. Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury. Advanced Materials. 2024;36(31). doi:10.1002/adma.202301738

BibTeX
@article{Kandell2024,
  author = {Kandell, Rebecca M and Wu, Jason R and Kwon, Ester J},
  title = {Reprograming Clots for In Vivo Chemical Targeting in Traumatic Brain Injury},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {31},
  doi = {10.1002/adma.202301738}
}
Kostenlos starten →